B cell and antibody immunodominance in antiviral immune response.

Natasha Tales*

Department of Biology, University of York, United States

Introduction

The immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including viruses. One crucial aspect of the immune response to viral infections is the production of antibodies by B cells. These specialized cells play a central role in recognizing and neutralizing viruses, thereby preventing further infection and facilitating the clearance of the virus from the body. In this article, we will explore the concepts of B cell and antibody immunodominance in the context of antiviral immune responses. B cells are a type of white blood cell that mature in the bone marrow and play a key role in adaptive immunity. When a virus enters the body, B cells are activated and undergo a process called clonal expansion. During clonal expansion, B cells divide and differentiate into plasma cells, which are antibody-secreting factories, and memory B cells, which provide long-term immunity. The antibodies produced by plasma cells are specific to the viral antigen that triggered their activation [1].

Immunodominance refers to the phenomenon where certain viral antigens elicit a more robust immune response compared to others. In the context of B cell and antibody responses, immunodominance can be observed at two levels: within an individual B cell repertoire and within the overall antibody response. At the individual B cell level, immunodominance is determined by the interaction between the antigen and the B cell receptor (BCR) expressed on the B cell surface. The BCR is a membrane-bound antibody molecule that recognizes specific viral antigens. Each B cell expresses a unique BCR generated by random rearrangement of gene segments during B cell development. This process generates a diverse repertoire of BCRs, allowing the immune system to recognize a wide range of viral antigens [2].

The affinity of the BCR for a particular viral antigen influences the immunodominance of that antigen. Antigens that bind strongly to the BCR are more likely to trigger B cell activation, leading to clonal expansion and the production of specific antibodies. Thus, viral antigens that exhibit high affinity for the BCRs of a significant proportion of B cells tend to dominate the B cell response. Furthermore, the competition between different B cells for limited resources, such as cytokines and T cell help, can also influence immunodominance. B cells that are activated earlier or receive more support from helper T cells may outcompete other B cells, leading to the preferential expansion of certain B cell clones and the production of antibodies specific to dominant viral antigens [3].

At the level of the overall antibody response, immunodominance is shaped by the interplay of multiple factors, including the antigenic properties of the virus, the B cell repertoire, and the immune microenvironment. Viral antigens that are more abundant, structurally accessible, or exhibit conserved epitopes across different viral strains are more likely to be immunodominant. These antigens are typically targeted by a larger number of B cells and result in a higher production of specific antibodies. Immunodominant antibodies play a crucial role in antiviral immune responses. They can directly neutralize the virus by binding to viral particles and preventing their entry into host cells. They can also tag virus-infected cells for destruction by other components of the immune system, such as natural killer cells and phagocytes. Additionally, immunodominant antibodies can activate the complement system, a group of proteins that enhances the immune response against viruses [4].

Understanding the factors that contribute to B cell and antibody immunodominance is of great importance for vaccine development and immunotherapy against viral infections. By identifying and targeting immunodominant viral antigens, vaccines can elicit a robust and protective immune response [5].

Conclusion

B cell and antibody immunodominance play critical roles in the antiviral immune response. The affinity of the B cell receptor for viral antigens, the competition among B cells for limited resources, and the overall antigenic properties of the virus influence the immunodominance of specific viral antigens. Immunodominant antibodies produced by B cells are essential for neutralizing the virus, tagging infected cells for destruction, and activating other components of the immune system.

References

1. Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337(6091):183-86.
2. Victora GD, Wilson PC. Germinal Center Selection and the Antibody Response to Influenza. Cell. 2015;163(3):545-48.

***Correspondence to:** Natasha Tales, Department of Biology, University of York, United States, E-mail: natashatales@york.ac.uk

***Received:** 29-May-2023, Manuscript No. AAICR-23-101422; **Editor assigned:** 01-Jun-2023, Pre QC No. AAICR-23-101422(PQ); **Reviewed:** 15-Jun-2023, QC No. AAICR-23-101422; **Revised:** 19-Jun-2023, Manuscript No. AAICR-23-101422(R); **Published:** 26-Jun-2023, DOI:10.35841/aaicr-6.3.154*

***Citation:** Tales N. B cell and antibody immunodominance in antiviral immune response. Immunol Case Rep. 2023;6(3):154*

3. Staudt LM, Gerhard W. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J Exp Med. 1983;157(2):687–704.

4. Whittle JR, Wheatley AK, Wu L, Lingwood D, et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol. 2014;88(8):4047-57.

5. Mozdzanowska K, Furchner M, Zharikova D, et al. Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol. 2005;79(10):5943-51

Citation: *Tales N. B cell and antibody immunodominance in antiviral immune response. Immunol Case Rep. 2023;6(3):154*